Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 6/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857009 | 0.87 | LRRK2 (0.43) | GUSBLRRK2APPPSMB8PTGS2 | |
| SCHEMBL25864784 | 0.79 | GUSB (0.45) | GUSBLRRK2APPPSMB8SNCA | |
| SCHEMBL12614804 | 0.72 | PIM1 (0.53) | PIM1PIM3PIM2 | |
| SCHEMBL23558148 | 0.70 | PSMB8 (0.40) | GUSBLRRK2APPPSMB8S1PR1 | |
| SCHEMBL25856557 | 0.70 | PSMB8 (0.40) | LRRK2APPPSMB8S1PR1S1PR3 | |
| SCHEMBL30355554 | 0.69 | LRRK2 (0.44) | LRRK2APPPSMB8BRD4PIM1 | |
| SCHEMBL23523820 | 0.69 | LRRK2 (0.44) | LRRK2APPPSMB8BRD4PIM1 | |
| SCHEMBL12172035 | 0.68 | MYC (0.53) | APPPSMB8 | |
| SCHEMBL8178920 | 0.65 | AHR (0.46) | PTGS2 | |
| SCHEMBL4259674 | 0.64 | APP (0.56) | GUSBLRRK2APPPSMB8S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | GUSB 3930/4885LRRK2 2882/4885APP 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.